PharmaShots Weekly Snapshots (Apr 05 – 09, 2021)

 PharmaShots Weekly Snapshots (Apr 05 – 09, 2021)

PharmaShots Weekly Snapshots (Apr 05 – 09, 2021)

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Published: Apr 9, 2021 | Tags: Evotec and Exscientia, Initiate, Human Clinical Trials, Novel, Immuno-Oncology Drug

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab

Published: Apr 9, 2021 | Tags: PlantForm, Signs, Research, Development Agreement, Bio-Manguinhos/Fiocruz, Develop, Biosimilar Pembrolizumab

BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC

Published: Apr 9, 2021 | Tags: BMS, Reports, Results, Opdivo (nivolumab), Yervoy (ipilimumab), P-III CheckMate -648 Trial, Unresectable, Advanced, Metastatic, ESCC

Merck Report Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 Trial as Adjuvant Treatment for Renal Cell Carcinoma

Published: Apr 9, 2021 | Tags: Merck, Report, Results, Keytruda (pembrolizumab), P-III KEYNOTE-564 Trial, Adjuvant, Treatment, Renal Cell Carcinoma

Hologic to Acquire Mobidiag for ~ $795M

Published: Apr 9, 2021 | Tags: Hologic, Acquire, Mobidiag, ~ $795M

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Published: Apr 9, 2021 | Tags: Biogen, Signs, License, Commercialization, Agreement, Bio-Thera, BAT1806 (biosimilar, tocilizumab), Treat, Moderate, Severe, Rheumatoid Arthritis

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

Published: Apr 8, 2021 | Tags: Lilly and Incyte, Report, Results, Baricitinib, P-III COV-BARRIER Study, Hospitalized, Patients, COVID-19

Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Published: Apr 8, 2021 | Tags: Daiichi Sankyo, Reports, First, Patient, Dosing, P- I/II Trial, DS-1594,  Treat, Acute, Myeloid Leukemia, Acute Lymphoblastic Leukemia

Merck KGaA Selects PRA’s Remote Patient Monitoring Platform for Human Growth Hormone Treatment System

Published: Apr 8, 2021 | Tags: Merck KGaA, Selects, PRA, Remote Patient Monitoring Platform, Human Growth Hormone Treatment System

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

Published: Apr 8, 2021 | Tags: AbbVie, Submits, Regulatory Applications, US, FDA, EMA, Skyrizi (risankizumab), Treat, Psoriatic Arthritis

Biogen’s Tysabri (natalizumab, SC) Receives EC’s Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Published: Apr 8, 2021 | Tags: Biogen, Tysabri (natalizumab, SC), Receives, EC, Marketing Authorization, Treat, Relapsing-Remitting, Multiple Sclerosis

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

Published: Apr 8, 2021 | Tags: BMS and PsiOxus Therapeutics, Expand, 2016, Immuno-Oncology Collaboration

Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies

Published: Apr 7, 2021 | Tags: Novartis, Collaborates, Artios Pharma, Discover, Next Generation, DDR Cancer Therapies

J&J Vision Collaborates with Menicon to Offer Contact Lenses for Managing the Progression of Myopia in Children

Published: Apr 7, 2021 | Tags: J&J Vision, Collaborates, Menicon, Offer, Contact Lenses, Managing, Progression, Myopia, Children

AstraZeneca Collaborates with MGH to Accelerate Digital Health Solutions

Published: Apr 7, 2021 | Tags: AstraZeneca, Collaborates, MGH, Accelerate, Digital Health Solutions

Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides

Published: Apr 7, 2021 | Tags: Progenity, Signs , Agreement, Ionis Pharmaceuticals, Evaluate, Oral Biotherapeutics Delivery System, Antisense Oligonucleotides

Pear Sign a Multiple Agreements to Expands its Prescription Digital Therapeutic Platform

Published: Apr 7, 2021 | Tags: Pear, Sign, Multiple Agreements, Expands, Prescription Digital Therapeutic Platform

The US FDA Extends Review Period of Olumiant’s sNDA to Treat Moderate to Severe Atopic Dermatitis

Published: Apr 7, 2021 | Tags: US, FDA, Extends, Review Period, Olumiant, sNDA, Treat, Moderate, Severe, Atopic Dermatitis

Passage Bio’s PBKR03 Receives EC’s Orphan Drug Designation for Krabbe Disease

Published: Apr 6, 2021 | Tags: Passage Bio, PBKR03, Receives, EC, Orphan Drug Designation, Krabbe Disease

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021

Published: Apr 6, 2021 | Tags: Horizon, Presents ,Results, Uplizna (inebilizumab-cdon),  N-MOmentum Trial, NMOSD

Exelixis Reports the US FDA’s Acceptance of IND for XB002 in Patients with Advanced Solid Tumors

Published: Apr 6, 2021 | Tags: Exelixis, Reports, US, FDA, Acceptance, IND, XB002, Patients,  Advanced, Solid Tumors

Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases

Published: Apr 6, 2021 | Tags: Ultragenyx, Collaborates, n-Lorem Foundation, Advance, Personalized, Medicines Treatment, Patients, Ultra-Rare Diseases

Welldoc Expands their Partnership with Dexcom to Offer Type 2 Diabetes Management Solution

Published: Apr 6, 2021 | Tags: Welldoc, Expands, Partnership, Dexcom, Offer, Type 2 Diabetes Management Solution

Sorrento to Acquire ACEA Therapeutics for ~$488M

Published: Apr 6, 2021 | Tags: Sorrento, Acquire, ACEA Therapeutics, ~$488M

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington’s Disease

Published: Apr 5, 2021 | Tags: uniQure, Reports, Completion, Enrollment, First, Cohort, P- I/II Trial, AMT-130, Treat, Huntington’s Disease

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

Published: Apr 5, 2021 | Tags: mAbxience, MB02 (biosimilar, bevacizumab), Receives, EC, Approval, Treatment, Cancer

Taiho Oncology’s Futibatinib (TAS-120) Receives the US FDA’s Breakthrough Therapy Designation for Advanced Cholangiocarcinoma

Published: Apr 5, 2021 | Tags: Taiho Oncology, Futibatinib (TAS-120), Receives, US, FDA Breakthrough Therapy Designation, Advanced, Cholangiocarcinoma

Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Pediatric Patients with Moderate to Severe Plaque Psoriasis

Published: Apr 5, 2021 | Tags: Lilly, Taltz (ixekizumab), Receives, Health Canada, Approval, Pediatri Patient, Moderate, Severe, Plaque Psoriasis

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Published: Apr 5, 2021 | Tags: Gilead, Expands, Collaboration, AbCellera, Develop, Antibodies, Against, Multiple Indications

Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Published: Apr 5, 2021 | Tags: Merck KGaA, Exercises, Third Option, Immuno-Oncology, Collaboration, F- star

Related Post: PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post